Navigation Links
ViThera Novel Approach Using Probiotics to Deliver Elafin Shows Promise as a Future Inflammatory Bowel Disease (IBD) Treatment
Date:10/31/2012

CAMBRIDGE, Mass., Oct. 31, 2012 /PRNewswire/ -- ViThera Pharmaceuticals, Inc, a developer of novel therapeutics based on engineered probiotic bacteria, announced today the publication of breakthrough data validating its approach for the delivery of elafin in treating gastrointestinal inflammation. The results were published today by the journal Science Translational Medicine and show use of recombinant probiotic and non-pathogenic food-strain bacteria to deliver elafin, a protein designed to protect human mucosal tissue during inflammation. The publication by senior author Nathalie Vergnolle and ViThera co-founder Philippe Langella describes a series of preclinical experiments successfully validating elafin as a novel treatment approach with future applications for human inflammatory bowel disease (IBD).

ViThera's President, Johannes Fruehauf, commented, "We are excited about the recognition that this publication entails and we congratulate Nathalie and Philippe on this important achievement." ViThera has obtained worldwide exclusive rights to the technology and is developing it further towards validation in clinical trials in close collaboration with Dr. Vergnolle and Dr. Langella. ViThera's VT301 program, currently in preclinical development, focuses on restoring and maintaining the integrity of the gut epithelium in patients with IBD by delivering elafin. This treatment is designed to help patients with active disease achieve remission faster and patients in remission to avoid flare-ups. VT301 is expected to enter clinical trials in two years for patients with mild to moderate ulcerative colitis.

About ViThera Pharmaceuticals

ViThera is a startup biotechnology company based in Cambridge, Massachusetts. Its research combines innovative molecular biology with the benefits of probiotics to create therapeutics for a variety of chronic diseases, including inflammatory bowel diseases like Crohn's disease and ulcerative colitis. ViThera i
'/>"/>

SOURCE ViThera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)
3. New magnetic-field-sensitive alloy could find use in novel micromechanical devices
4. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
5. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
6. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
7. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
8. Boulder Diagnostics Licenses Novel Rapid Detection Technology for Homocysteine and Related Compounds from Portland State University
9. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
10. Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
11. Novel method to make nanomaterials discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “Service Quality Management ... Product Type & Provider Type - Global ... and segments the market with an in-depth ... Browse 152 market data tables, 19 figures ... on “Service Quality Management (SQM) and Telco ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014 ... ) announced today that Medtronic, Inc. (NYSE: ... application to the U.S. Food and Drug Administration ... II implantable drug infusion system (including a ... Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 /PRNewswire/ ... company advancing patient care in critical areas, announced the ... of common stock, and warrants to purchase up to ... offering price of $4.00 per share and $.01 per ... of $5.00, are exercisable immediately, and expire 5 years ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ... general corporate purposes. Under the terms ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... PRA, a leading Clinical Research Organization, continues our expansion ... of an office in Singapore. The office will serve ... strengthening the quality and timeliness of our deliverables to ... the heart of the city-state, will provide monitoring, project ...
... PARK, Calif., Feb. 23, 2012 Telome Health, Inc.™, ... telomere biology in human health, has announced that co-founder and ... Year by Silicon Valley Business Journal. ... award, especially coming from the heart of innovation, Silicon Valley, ...
... Calif., Feb. 21, 2012 Keck Graduate Institute (KGI) ... (CGS) and the Alfred P. Sloan Foundation to administer ... part of establishing and maintaining high quality standards for ... honored to be selected and we look forward to ...
Cached Biology Technology:PRA Opens Office in Singapore 2Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year 2KGI Selected to Administer PSM Affiliation Process 2
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  Since its ... has helped thousands of people to eliminate the pain ... replacing the antiquated system with their own biometrics fused ... to remember usernames and passwords, Hoyos Labs , ... identity, announced today that it is offering the app ...
(Date:12/22/2014)... SHELTON, Conn. , Dec. 22, 2014  NXT-ID, ... or the "Company"), a biometric authentication company focused on ... famous pickpocket, entertainer and security consultant, Apollo Robbins ... Wocket™ biometric smart wallet.  Apollo ... 6th and 7 th , 2015, demonstrating some of ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the addition of the "The Global ... their offering. ... an overview of the global digital media ... control and monitor piracy by securely and ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4The Global Watermarking and Fingerprinting Markets 2
... Atlantis rockets into space later this week, it will ... study how their genetic responses and their ability to ... part of the STS-115 space shuttle mission scheduled for ... Salmonella typhimurium, Pseudomonas aeruginosa and Candida albicans -- that ...
... Virginia Health System have shown for the first time ... muscle cells can reverse myotonic dystrophy, the most common ... 40,000 people in the United States have myotonic muscular ... wasting of the muscles, irregular heartbeat, cataracts and insulin ...
... the Rubeho Mountains in Tanzania revealed over 160 ... eleven endemic species--according to an article published in ... findings elevate the importance of protecting this biologically-rich ... range from destructive activities underway such as clear-cutting ...
Cached Biology News:Microscopic passengers to hitch ride on space shuttle 2Microscopic passengers to hitch ride on space shuttle 3Toxic molecule may cause most common type of muscular dystrophy 2First surveys of Tanzanian mountains reveal 160+ animal species, including new & endemic 2
...
... The ideal modular cleanroom for biological ... that require cleanliness (to Class 10/ISO ... precision-joined to create ultra-smooth surfaces that ... disinfect. One-inch radius corners simplify cleaning. ...
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... Analysis Note: Protein determined by ... 3.2 M (NH 4 ) ... 7.0 Preparation Note: Affinity purified ... suspension • Additives: MgCl 2 ...
Biology Products: